Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979241 | 0.96 | OPRK1 (0.55) | OPRK1MAPK14SMOCSF1RLCK | |
| SCHEMBL6476766 | 0.95 | OPRK1 (0.59) | OPRK1MAPK14SMOCSF1RGPR119 | |
| SCHEMBL7856980 | 0.93 | OPRK1 (0.54) | OPRK1MAPK14SMOGPR119RAF1 | |
| SCHEMBL7804552 | 0.93 | OPRK1 (0.54) | OPRK1MAPK14SMOGPR119NTRK1 | |
| SCHEMBL6476511 | 0.91 | MAPK14 (0.62) | OPRK1MAPK14SMOGPR119RAF1 | |
| SCHEMBL6533594 | 0.91 | OPRK1 (0.56) | OPRK1MAPK14SMOCSF1RNTRK1 | |
| SCHEMBL7857012 | 0.89 | OPRK1 (0.51) | OPRK1MAPK14SMOGPR119RAF1 | |
| SCHEMBL7806472 | 0.89 | OPRK1 (0.51) | OPRK1MAPK14SMOGPR119NTRK1 | |
| SCHEMBL7809442 | 0.88 | MAPK14 (0.52) | OPRK1MAPK14SMOGPR119 | |
| SCHEMBL6477083 | 0.88 | MAPK14 (0.54) | OPRK1MAPK14SMOCSF1RBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | OPRK1 1254/4885MAPK14 1775/4885SMO 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.